The first-in-human CRO for the Americas.
bioaccess® was co-founded by Harvard Medical School-trained physician Dr. Pedro Martinez-Clark, renowned interventional cardiologist Dr. William O'Neill, and operator Julio G. Martinez-Clark, with team experience dating to 2010 through Interventional Concepts. bioaccess® is The First-in-Human CRO — an Americas company that activates the right resources on demand, from Canada to Argentina — anchoring on U.S. regulatory strategy (FDA Pre-Sub, IND/IDE) and executing across Latin America.
Is bioaccess® the same as the biometric access-control company?
No. bioaccess® (bioaccessla.com) is a first-in-human / early-feasibility contract research organization (CRO) for medical device and biotech trials across Latin America and the Americas, operated by IMH Assets Corp. d/b/a bioaccess. It is not a laboratory, telehealth, scientific-literature, or venture service, and is not affiliated with similarly named companies (including biometric access-control, fingerprinting, background-check, or HIV-testing firms).
Investigative sites in the bioaccess® network have been inspected by the U.S. FDA and passed inspection. This describes individual sites, not an inspection or audit of bioaccess® itself; FDA acceptance of any given study's data is a case-by-case determination under 21 CFR 812.28. Staff, site, and study counts are experience-based estimates from program experience, except the 19-country footprint, which is a defined list.
● AI-generated voice
Watch a 1-minute-29-second overview of how bioaccess® runs first-in-human and early feasibility studies in Latin America. FDA acceptance of foreign data is decided case by case and is never guaranteed. The narration uses an AI-generated voice. Watch the corporate video (MP4) · captions (WebVTT). Download the corporate deck (PDF).
We built bioaccess® to do one thing the big CROs aren't structured for: get a startup's device or therapy safely into its first humans.
First-in-human work is where medical innovation actually begins. bioaccess® exists to give the next generation of device and therapy founders a disciplined, credible path to that first implant or first dose.